The Autism Impact Fund Makes First Investments In Seven Early-Stage Companies

The Autism Impact Fund (AIF), whose mission is to revolutionize the status quo for diagnosing, treating, and living with autism through a venture capital model, invested in seven growth and early-stage companies. AIF seeks to accelerate the development and delivery of emerging technologies, translational science and innovative services to help individuals with autism reach their full potential. The financial terms of each investment were not disclosed.

The investments were in the following companies.

Axial, which is a clinical-stage biopharmaceutical company focused on developing a pipeline of gut-restricted small molecule agents intended for the treatment of autism, other . . .